Gene therapy constructs for treating wilson disease

Abstract

To provide gene therapy constructs for treating Wilson disease.SOLUTION: This application relates to adeno-associated viral vectors encoding a truncated yet functional ATP7B for use in gene therapy for treating Wilson disease (WD). The truncated ATP7B described herein has several advantages over the wild-type ATP7B, such as higher efficacy and improved manufacturing yield. This application relates generally to adeno-associated viral vectors and methods of use thereof in gene therapy for treating Wilson disease (WD).SELECTED DRAWING: None

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 788,324, filed January 4, 2019; and U.S. Provisional Patent Application No. 62 / 834,830, filed April 16, 2019, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0002] Sequence Listing This application contains a Sequence Listing that has been submitted electronically in ASCII format and is incorporated by reference in its entirety. The ASCII copy (created on December 31, 2019) is titled ULP-003WO_SL_ST25.txt and is 49,846 bytes in size.

[0003] TECHNICAL FIELD OF THEINVENTION This application relates generally to adeno-associated virus vectors and their use in gene therapy for the treatment of Wilson's disease (WD). [Background technology]

[0004] 2. Background of the Invention Wilson's disease (WD) is an autosomal recessive genetic disorder that causes copper accumulation primarily in the liver and subsequently in the nervous system and other tissues. WD is a rare disorder that affects approximately 1 in 30,000 people and is caused by mutations in the copper-transporting ATPase 2 (ATP7B) gene on chromosome 13. There are more than 600 unique ATP7B mutations. ATP7B is expressed primarily in hepatocytes and functions in transmembrane transport of copper. Absence or reduction of ATP7B protein function results in reduced excretion of copper by hepatocytes into bile, causing liver disease. Over time without proper treatment, high copper levels can cause life-threatening organ damage.

[0005] Patients with hepatic WD usually present in late childhood or adolescence and show features of acute hepatitis, fulminant hepatic failure, or progressive chronic liver disease. The neurological manifestations of WD typically appear later than the liver disease, with the majority appearing in the second or third decade, and include extrapyramidal, cerebellar, and cerebral-related symptoms.

[0006] The goal of medical treatment for WD is to remove toxic deposits of copper from the body and prevent its reaccumulation. The current treatment approach for WD is daily oral treatment with chelating agents (D-penicillamine, trientine, and zinc salts). Medical treatment is effective in the majority, but not all, WD patients. Liver transplantation is a treatment option in WD patients who present with fulminant or progressive liver failure. However, transplant recipients are required to maintain a constant immunosuppressive regimen to prevent rejection.

[0007] The present invention addresses the need for improved and sustainable treatment of WD by delivering a gene expressing a truncated but still functional ATP7B to patients using an adeno-associated virus vector. The truncated ATP7B of the present invention has improved efficacy in treating WD and has the advantages of ease of manufacture and efficiency over wild-type and other truncated forms of ATP7B protein. Summary of the Invention [Means for solving the problem]

[0008] Summary of the Invention The present invention provides compositions and their use in gene therapy. Adeno-associated virus (AAV) vectors useful in the treatment of WD are provided herein. In one aspect, the present invention provides a recombinant nucleic acid construct comprising a 5'-inverted terminal repeat (ITR) sequence; a promoter sequence; a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) in which metal-binding domains (MBDs) 1-3 are deleted but a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4 is present; and a 3'-ITR sequence.

[0009] In another aspect, the present invention provides a recombinant adeno-associated virus (rAAV) useful for treating Wilson's disease, wherein the rAAV comprises an AAV capsid and a vector genome packaged therein, the vector genome comprising: a 5'-inverted terminal repeat (ITR) sequence; a promoter sequence; a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) lacking metal binding domains (MBDs) 1-3 but with a serine-rich loop between MBD3 and MBD4 that contains two serine residues (S340 and S341); and a 3'-ITR sequence.

[0010] These and other aspects and features of the present invention are described in the following sections of this application.

[0011] The present invention may be more fully understood with reference to the following drawings. [Brief description of the drawings]

[0012] [Figure 1]FIG. 1 is an exemplary diagram showing an exemplary vector genome construct comprising a nucleotide sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) ("ATP7B Δ1-3-SS" or "ATP7B del1-3 native") in which metal binding domains (MBDs) 1-3 are deleted, but a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4 is present. Features of the exemplary vector genome construct are provided below: [Table 1]

[0013] [Diagram 2] FIG. 2 is a schematic diagram of an exemplary AAV vector (DTC319), in which various key components are indicated.

[0014] [Diagram 3] FIG. 3 is a schematic diagram of an exemplary plasmid, pAAV2 / 8.KanR(p2123FH) AAV Rep / Cap plasmid, which provides Rep and Cap functions in packaging rAAV when co-transfected into a host cell with an AAV vector.

[0015] [Figure 4] FIG. 4 is a schematic diagram of an exemplary plasmid for rAAV production, pAdDeltaF6(Kan) adenovirus helper plasmid, when co-transfected into host cells with an AAV vector and Rep / Cap plasmids.

[0016] [Diagram 5]5 is a scatter plot of liver copper (μg / g) in C3He-Atp7btx-j female mice (represented by circles) injected with either 109, 1010, or 1011 genome copies (GC) / kg of ATP7BcoFL (codon-optimized full-length human ATP7B) and C3He-Atp7btx-j male mice (represented by squares) injected with either 1010 or 1011 GC / kg of that same vector. Copper levels from age-matched uninjected male and female heterozygous (Het) and C3He-Atp7btx-j mice are also represented in the scatter plot.

[0017] [Figure 6] FIG. 6 is a bar graph showing the total yield rAAV (titration in GC) generated from host cells following transfection with AAV vectors encoding the complete or partial coding sequence of human ATP7B (AAV vectors having a nucleotide sequence encoding full-length (FL) human ATP7B; AAV vectors having a nucleotide sequence encoding human ATP7B in which MBDs 1-3 are deleted but a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4 is present (ATP7B Δ1-3-SS); or AAV vectors having a nucleotide sequence encoding human ATP7B in which MBDs 1-4 are deleted (ATP7B Δ1-4).

[0018] [Figure 7] Figure 7 is a scatter plot of urinary and hepatic copper levels (squares and circles, respectively, in μg / g) assayed after injection of AAV8 carrying full-length human ATP7B (ATP7B FL), ATP7B Δ1-3-SS, or ATP7B Δ1-4 into C3He-Atp7btx-j mice. C3He-Atp7btx-j mice administered phosphate-buffered saline (PBS) served as control (vehicle).

[0019] [Figure 8]FIG. 8 is a bar graph showing the total yield rAAV (titrated in GC) generated from host cells following transfection of an AAV vector (DTC319) encoding a truncated human ATP7B lacking metal binding domains (MBDs) 1-3 but containing a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4, and encoding either an AAV8 or AAV9 capsid.

[0020] [Figure 9] Figure 9 is a bar graph of hepatic copper accumulation levels (μg / g dry weight) in C3He-Atp7btx-j mice administered intravenous injection of vehicle control (dilution buffer; WD) or injection of AAV8 with native ATP7B Δ1-3-SS (DelA). Hepatic copper accumulation levels of uninjected wild-type mice (WT) represented in the bar graph served as negative control. Values ​​are expressed as mean ± SEM (standard error of the mean).

[0021] [Figure 10] Figure 10 is a bar graph of ceruloplasmin activity in C3He-Atp7btx-j mice administered intravenous injections of vehicle control (dilution buffer; WD) or AAV8 with native ATP7B Δ1-3-SS (DelA), as measured by an enzyme reaction-based colorimetric activity assay. Ceruloplasmin activity in uninjected wild-type (WT) mice is also represented in the bar graph, as measured by the same enzyme reaction-based colorimetric activity assay.

[0022] [Figure 11] FIG. 11 is a bar graph of the mean scores after standard evaluation of hematoxylin and eosin (H&E) slides for nuclear enlargement and hepatocellular hypertrophy, tissue disruption, inflammatory infiltrate, and hepatocellular necrosis.

[0023] [Figure 12]FIG. 12 is an exemplary schematic diagram showing an exemplary vector genome construct DTC327 that includes an AAV9 capsid with PPIA polyA, AAV2 Rep / ITRs with the complete p5 promoter including 145 bp ITRs, and a nucleotide sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) that lacks metal binding domains (MBDs) 1-3 but has a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0024] Detailed Description of the Invention The present invention provides agents and compositions for use in treating Wilson's disease (WD). The nucleic acid sequences, vectors, recombinant viruses, and related compositions of the present invention as described herein can be used to ameliorate, prevent, or treat WD.

[0025] Unless otherwise noted, technical terms are used according to conventional usage. Definitions of common terms in molecular biology are found in Benjamin Lewin, Genes V, ed. Oxford University Press 1994 (ISBN 0-19-854287-9); Kendrew et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

[0026] In order to facilitate review of the various embodiments of the disclosure, the following explanations of specific terms are provided:

[0027] Adeno-associated virus (AAV): A small, replication-deficient, non-enveloped virus that infects humans and some other primate species. AAV is not known to cause disease and induces a very mild immune response. Gene therapy vectors utilizing AAV can infect both dividing and quiescent cells and can persist in an extrachromosomal state without integrating into the host cell genome. These characteristics make AAV an attractive viral vector for gene therapy. There are currently 12 recognized AAV serotypes (AAV1-12).

[0028] Administer / Administer: Providing or giving an agent (e.g., a therapeutic agent (e.g., a recombinant AAV)) to a subject by any effective route. Exemplary routes of administration include, but are not limited to, injection (e.g., subcutaneous, intramuscular, intradermal, intraperitoneal, and intravenous), oral, intraductal, sublingual, rectal, transdermal, intranasal, vaginal, and inhalation routes.

[0029] ATP7B Δ1-3-SS: As used herein, ATP7B Δ1-3-SS refers to a truncated human copper-transporting ATPase 2 (ATP7B) lacking metal-binding domains (MBDs) 1-3, but containing a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4.

[0030] Codon-optimized: A "codon-optimized" nucleic acid refers to a nucleic acid sequence in which the codons have been changed to be optimal for expression in a particular system (e.g., a particular species or group of species). For example, a nucleic acid sequence can be optimized for expression in a mammalian cell or a particular mammalian species (e.g., a human cell). Codon optimization does not change the amino acid sequence of the encoded protein.

[0031] Enhancer: A nucleic acid sequence that increases the rate of transcription by increasing the activity of a promoter.

[0032] Intron: A stretch of DNA within a gene that does not contain any coding information for a protein. Introns are removed before the messenger RNA is translated.

[0033] Inverted terminal repeats (ITR): Symmetrical nucleic acid sequences in the genome of adeno-associated viruses that are required for efficient replication. ITR sequences are located at each end of the AAV DNA genome. The ITRs serve as replication origins for viral DNA synthesis and are required for vector encapsulation.

[0034] Isolated: An "isolated" biological component (e.g., a nucleic acid molecule, a protein, a virus, or a cell) has been substantially separated or purified from other biological components (e.g., other chromosomal and extrachromosomal DNA and RNA, proteins, and cells) in the cells or tissues of the organism in which it naturally occurs, or in the organism itself. "Isolated" nucleic acid molecules and proteins include those purified by standard purification methods. The term also includes nucleic acid molecules and proteins prepared by recombinant expression in a host cell, as well as chemically synthesized nucleic acid molecules and proteins.

[0035] Operably linked: A first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence. For example, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Generally, operably linked DNA sequences are contiguous and, where necessary to join two protein coding regions, in the same reading frame.

[0036] Pharmaceutically acceptable carriers: The pharma- ceutically acceptable carriers (vehicles) useful in the present disclosure are conventional. Remington's Pharmaceutical Sciences by EW Martin (Mack Publishing Co., Easton, Pa., 15th ed. (1975)) describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds, molecules or agents.

[0037] Generally, the nature of the carrier depends on the particular mode of administration used. For example, parenteral formulations usually contain injectable fluids that contain pharma- ceutically and physiologically acceptable fluids (e.g., water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol, etc.) as vehicles. For solid compositions (e.g., powder, pill, tablet, or capsule forms), conventional non-toxic solid carriers can contain, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate. In addition to biologically neutral carriers, pharmaceutical compositions to be administered can contain minor amounts of non-toxic auxiliary substances (e.g., wetting or emulsifying agents, preservatives, and pH buffering agents, such as sodium acetate or sorbitan monolaurate).

[0038] Preventing, Treating or Ameliorating a Disease: "Preventing" a disease (e.g., WD) refers to inhibiting the full development of the disease. "Treating" refers to a therapeutic intervention that improves a sign or symptom of the disease or a pathological condition (e.g., WD) after the disease has begun to develop. "Ameliorating" refers to a reduction in the number or severity of signs or symptoms of a disease (e.g., WD).

[0039] Promoter: A region of DNA that directs / initiats the transcription of a nucleic acid (e.g., a gene). A promoter contains necessary nucleic acid sequences near the transcription start site.

[0040] Purified: The term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified peptide, protein, virus, or other active compound is one that has been completely or partially isolated from naturally associated proteins and other contaminants. In certain embodiments, the term "substantially purified" refers to a peptide, protein, virus, or other active compound that has been isolated from cells, cell culture medium, or other crude preparations and subjected to fractionation to remove various components (e.g., proteins, cell debris, and other components) of the original preparation.

[0041] Recombinant: A recombinant nucleic acid molecule is one that has a sequence that is not found in nature or that is made by the artificial combination of two otherwise isolated segments of sequence, which can be accomplished by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acid molecules (e.g., by genetic engineering techniques).

[0042] Similarly, a recombinant virus is a virus that contains a sequence that does not exist in nature (e.g., a genomic sequence) or a sequence that is created by the artificial combination of at least two sequences from different origins. The term "recombinant" also includes nucleic acids, proteins and viruses that are modified only by adding, substituting or deleting a part of a natural nucleic acid molecule, protein or virus. As used herein, "recombinant AAV" refers to an AAV particle that contains a recombinant nucleic acid molecule (e.g., a recombinant nucleic acid molecule that encodes a truncated human ATP7B (e.g., SEQ ID NO:1 or SEQ ID NO:15)).

[0043] Sequence identity: The identity or similarity between two or more nucleic acid sequences or two or more amino acid sequences is expressed in terms of the identity or similarity between the sequences. Sequence identity can be measured in terms of percentage identity; the higher the percentage, the more identical the sequences are. Sequence similarity can be measured in terms of percentage similarity (taking into account conservative amino acid substitutions); the higher the percentage, the more similar the sequences are. Homologs or orthologs of nucleic acid or amino acid sequences have a relatively high degree of sequence identity / similarity when aligned using standard methods. This homology is more pronounced when the ortholog protein or cDNA is derived from a more closely related species (e.g., human and mouse sequences) compared to a more distantly related species (e.g., human and C.elegans sequences).

[0044] Methods for aligning sequences for comparison are well known in the art. Various programs and alignment algorithms are described in: Smith & Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol. Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp, CABIOS5:151-3, 1989; Corpet et al., Nuc. Acids. Res. 16:10881-90, 1988; Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992: and Pearson et al., Meth. Mol. Rio. 24:307-31, 1994. Altschul et al., J. Mol. Biol. 215:403-10, 1990 present detailed considerations of sequence alignment methods and homology calculations.

[0045] The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403-10, 1990) is available from several sources, including the National Center for Biological Information (NCBI), and on the Internet, for use with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. Further information can be found at the NCBI website.

[0046] Serotype: A group of closely related microorganisms (e.g., viruses) distinguished by a characteristic set of antigens.

[0047] Stuffer sequence: A sequence of nucleotides contained within a larger nucleic acid molecule (e.g., a vector) that is typically used to create a desired spacing between two nucleic acid features (e.g., between a promoter and a coding sequence) or to extend a nucleic acid molecule so that the nucleic acid molecule is of a desired length. Stuffer sequences do not contain protein coding information and may be of unknown / synthetic origin / and / or unrelated to other nucleic acid sequences within the larger nucleic acid molecule.

[0048] Subject: Living multicellular, vertebrate organisms (a category that includes humans and non-human mammals).

[0049] Synthetic: produced by artificial means in a laboratory. For example, synthetic nucleic acids can be chemically synthesized in a laboratory.

[0050] Therapeutically effective amount: An amount of a particular pharmaceutical or therapeutic agent (e.g., a recombinant AAV) sufficient to achieve a desired effect in a subject or cell being treated with the agent. The effective amount of the agent depends on several factors, including, but not limited to, the subject or cell being treated and the mode of administration of the therapeutic composition.

[0051] Vector: A vector is a nucleic acid molecule that allows the insertion of foreign nucleic acid without destroying the ability of the vector to replicate and / or integrate in a host cell. A vector may contain a nucleic acid sequence that allows it to replicate in a host cell (e.g., origin of replication). A vector may also contain one or more selectable marker genes and other genetic elements. An expression vector is a vector that contains the necessary regulatory sequences to allow the transcription and translation of inserted genes. In some embodiments herein, the vector is an AAV vector.

[0052] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The singular forms "a," "an," and "the" include plural references unless the context clearly indicates otherwise. "Comprising A or B" means including A, or B, or A and B. It should be further understood that all base or amino acid sizes and all molecular weight or molecular mass values ​​given for nucleic acids or polypeptides are approximate and are provided for illustration purposes. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification (including explanations of terms) will control, and further, the above materials, methods, and examples are intended to be illustrative only and not limiting.

[0053] Viral Vectors In some aspects, the disclosure provides a recombinant adeno-associated virus (AAV) vector comprising a genome including an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence encoding ATP7B Δ1-3-SS (e.g., SEQ ID NO:1 or SEQ ID NO:15), and an AAV 3'-inverted terminal repeat (ITR) sequence.

[0054] In some embodiments, the genome may further comprise an enhancer, an intron, a consensus Kozak sequence, and / or a polyadenylation signal as described herein. In some embodiments, the recombinant vector may further comprise one or more stuffer nucleic acid sequences. In one embodiment, a stuffer nucleic acid sequence is located between the intron and the partial or complete coding sequence of ATP7B.

[0055] In various embodiments described herein, the recombinant viral vector is an adeno-associated viral (AAV) vector.The AAV vector can be any one of serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 AAV vectors (i.e., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, or AAV12) and more than 100 variants isolated from human and non-human primate tissues.See, for example, Choi et al., 2005, Curr Gene Ther. 5: 299-310, 2005 and Gao et al., 2005, Curr Gene Ther. 5: 285-297.Any serotype of AAV vector can be used in the present invention, and the choice of AAV serotype depends in part on the cell type targeted for gene therapy. For the treatment of WD, liver is one of the relevant target organs.In some embodiments, the AAV vector is selected from serotype 9 (AAV9), serotype 8 (AAV8), serotype 5 (AAV5) or their variants.In exemplary embodiments, the AAV vector is serotype 9 (AAV9) or their variants.

[0056] In some embodiments, the recombinant AAV vector contains AAV ITR sequences, which function as both a vector DNA origin of replication and a packaging signal for the vector genome when AAV and adenovirus helper functions are provided in trans. In addition, the ITRs serve as targets for single-stranded endonucleatic nicking by the large Rep protein to separate individual genomes from replicative intermediates.

[0057] In some embodiments, the 5'-ITR sequence is derived from AAV2. In some embodiments, the 3'-ITR sequence is derived from AAV2. In some embodiments, the 5'-ITR sequence and the 3'-ITR sequence are derived from AAV2. In some embodiments, the 5'-ITR sequence and / or the 3'-ITR sequence are derived from AAV2 and comprise or consist of SEQ ID NO:2. In other embodiments, the 5'-ITR sequence and / or the 3'-ITR sequence are derived from a non-AAV2 source.

[0058] In some exemplary embodiments, the AAV vector is an AAV serotype 9 (AAV9) vector, which comprises an enhancer, a promoter, an intron, a nucleic acid sequence encoding ATP7B Δ1-3-SS (e.g., SEQ ID NO:1 or SEQ ID NO:15), and a polyadenylation signal as described herein. In some embodiments, the AAV9 vector further comprises two AAV2, AAV8, or AAV9 inverted terminal repeat (ITR) sequences: one 5' to the enhancer and one 3' to the polyadenylation signal. In exemplary embodiments, the AAV9 vector comprises two AAV2 inverted terminal repeat (ITR) sequences: one 5' to the enhancer and one 3' to the polyadenylation signal. In some embodiments, the AAV2 ITR sequence comprises or consists of SEQ ID NO:2. In another exemplary embodiment, the AAV9 vector contains two AAV9 inverted terminal repeat (ITR) sequences: one 5' to the enhancer and one 3' to the polyadenylation signal.

[0059] In some exemplary embodiments, the present disclosure provides a recombinant nucleic acid comprising a vector genome comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence represented by SEQ ID NO: 1 and encoding native ATP7B Δ1-3-SS, and an AAV 3'-inverted terminal repeat (ITR) sequence. In some exemplary embodiments, the present disclosure provides a recombinant nucleic acid comprising a vector genome comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence represented by SEQ ID NO: 15 and encoding codon-optimized ATP7B Δ1-3-SS, and an AAV 3'-inverted terminal repeat (ITR) sequence. In some exemplary embodiments, the present disclosure provides a vector genome consisting of SEQ ID NO: 14, comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence represented by SEQ ID NO: 1 and encoding native ATP7B Δ1-3-SS, or an adeno-associated virus (AAV) vector comprising the vector genome.

[0060] In a further aspect, the present application provides recombinant nucleic acid sequences corresponding to vector genomes useful in the treatment of WD. In some embodiments, the present application provides recombinant nucleic acids that are 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher identical to SEQ ID NO: 14. Thus, the present application provides recombinant nucleic acids that are at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9%, or 100%) identical to SEQ ID NO: 14. In an exemplary embodiment, the present application provides a recombinant nucleic acid sequence corresponding to a vector genome comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence represented by SEQ ID NO: 1 and encoding native ATP7B Δ1-3-SS, and an AAV 3'-inverted terminal repeat (ITR) sequence, wherein said vector genome comprises or consists of SEQ ID NO: 14. In an exemplary embodiment, the present application provides a recombinant nucleic acid sequence corresponding to a vector genome comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a nucleic acid sequence represented by SEQ ID NO: 15 and encoding codon-optimized ATP7B Δ1-3-SS, and an AAV 3'-inverted terminal repeat (ITR) sequence.

[0061] promoter: In various aspects described herein, an AAV vector is provided that includes a promoter sequence that helps drive and regulate transgene expression, such as the expression of ATP7B Δ1-3-SS (e.g., the amino acid sequence of ATP7B Δ1-3-SS represented by SEQ ID NO:8). In exemplary embodiments, the promoter sequence is located between a selected 5'-ITR sequence and the coding sequence of ATP7B Δ1-3-SS (e.g., SEQ ID NO:1 or SEQ ID NO:15). In some embodiments, the promoter sequence is located downstream of an enhancer sequence. In some embodiments, the promoter sequence is located upstream of an intron sequence. In some illustrative embodiments, the vectors described herein use a transthyretin (TTR) promoter, which can be optionally located downstream of a transthyretin enhancer (enTTR).

[0062] In some embodiments, the promoter is selected from the transthyretin (TTR) promoter, chicken β-actin (CBA) promoter, cytomegalovirus immediate early gene (CMV) promoter, thyroxine-binding globulin (TBG) promoter, alpha 1 antitrypsin (A1AT) promoter, and CAG promoter (constructed using the CMV early enhancer element, its promoter, first exon, and first intron of the CBA gene, and the splice acceptor of the rabbit β-globin gene). In an exemplary embodiment, the promoter is the TTR promoter. In one embodiment, the TTR promoter comprises or consists of SEQ ID NO: 12.

[0063] In addition to the promoter, the AAV vector may contain other suitable transcription initiation, termination, enhancer sequences, and efficient RNA processing signals. As described in more detail below, such sequences include splicing and polyadenylation (polyA) signals, regulatory elements that enhance expression (i.e., WPRE), sequences that stabilize cytoplasmic mRNA, sequences that enhance translation efficiency (i.e., Kozak consensus sequences), and sequences that enhance protein stability.

[0064] In some embodiments, the AAV vector comprises a vector genome further comprising a consensus Kozak sequence. In some embodiments, the consensus Kozak sequence is located downstream of an intron sequence. In one embodiment, the consensus Kozak sequence is GCCGCC (SEQ ID NO: 11). As will be understood by those skilled in the art, the consensus Kozak sequence is typically located immediately upstream of a coding sequence; in this case, immediately upstream of the coding sequence of truncated ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1 or SEQ ID NO: 15). As will be recognized by those skilled in the art, the consensus Kozak sequence can be considered to share the ATG residue that corresponds to the start codon of a therapeutic polypeptide, for example, truncated ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1 or SEQ ID NO: 15). For simplicity of disclosure, the consensus Kozak sequence, as described herein, includes a sequence of six nucleotides that corresponds to a region that is not shared with a nucleic acid encoding a therapeutic polypeptide, e.g., a truncated ATP7B (ATP7B Δ1-3-SS encoded by SEQ ID NO:1 or SEQ ID NO:15).

[0065] ATP7B Polypeptide: As described herein, aspects of the invention provide a recombinant vector comprising a genome comprising an AAV 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) having the amino acid sequence of SEQ ID NO:8 (e.g., SEQ ID NO:1 or SEQ ID NO:15), and an AAV 3'-inverted terminal repeat (ITR) sequence. ATP7B has eight transmembrane domains that form a pathway across the cell membrane for copper translocation; and a large N-terminus with six metal binding domains (MBDs) (each containing approximately 70 amino acids) and a highly conserved metal binding motif GMxCxxC (where x is any amino acid). The standard sequence (also referred to as isoform a, which is the longest isoform; NCBI Reference Sequence: In addition to NP_000044.2), four additional isoforms are known: NCBI Reference Sequences Four additional isoforms are known: NCBI Reference Sequences NP_ 001005918.1, NP _001230111.1, NP _001317507.1, NP_ 001317 508.1. The compositions and methods described herein can be used to treat subjects with disease-causing non-functional ATP7B variant proteins.

[0066] In one embodiment, the coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO:1 or SEQ ID NO:15) encodes a protein having amino acids as set forth in SEQ ID NO:8. SEQ ID NO:1 provides a cDNA for native human ATP7B with MBDs 1-3 deleted. SEQ ID NO:8 represents the DEL1-3 native or ATP7B Δ1-3-SS protein in which two serine residues are present corresponding to positions 340 and 341 of the wild type ATP7B full length protein sequence.

[0067] In various embodiments described herein, a vector is provided that comprises a genome that includes a coding sequence for truncated ATP7B (ATP7B Δ1-3-SS) (eg, SEQ ID NO:1 or SEQ ID NO:15).

[0068] In some embodiments, vectors are provided that contain a genome that includes an engineered cDNA of codon-optimized human ATP7B (e.g., SEQ ID NO: 15). Polypeptides delivered by the vectors described herein include truncated ATP7B with MBDs 1-3 deleted (ATP7B Δ1-3-SS), which is suitable for use in treating WD.

[0069] In some embodiments, the polypeptide expressed in a vector described herein is truncated human ATP7B (SEQ ID NO:8).

[0070] Vector Elements: In some embodiments, the AAV vector comprises a genome further comprising one or more enhancer sequences.In one embodiment, the enhancer is selected from transthyretin enhancer (enTTR), cytomegalovirus immediate early gene (CMV) enhancer, chicken beta-actin (CBA) enhancer, En34 enhancer, and apolipoprotein (ApoE) enhancer.In an exemplary embodiment, the enhancer is the enTTR enhancer.In one embodiment, the enTTR enhancer comprises or consists of SEQ ID NO:3.

[0071] In some embodiments, the AAV vector comprises a genome further comprising one or more intron sequences. In one embodiment, the intron is selected from the SV40 Small T intron, rabbit hemoglobin subunit β (rHBB) intron, human β-globin IVS2 intron, β-globin / IgG chimeric intron (Promega chimeric intron), or hFIX intron. In one exemplary embodiment, the intron is the SV40 Small T intron. In one embodiment, the SV40 Small T intron sequence comprises or consists of SEQ ID NO:4. In another exemplary embodiment, the intron is the rHBB intron. In one embodiment, the rHBB intron sequence comprises or consists of SEQ ID NO:5.

[0072] In some embodiments, the AAV vector comprises a genome further comprising a polyadenylation signal sequence. In one embodiment, the polyadenylation signal sequence is selected from the SV40 polyadenylation signal sequence, the bovine growth hormone (BGH) polyadenylation signal sequence, and the rabbit β-globin polyadenylation signal sequence. In an exemplary embodiment, the polyadenylation signal sequence is the bovine growth hormone (BGH) polyadenylation signal sequence. In one embodiment, the BGH polyadenylation signal sequence comprises or consists of SEQ ID NO:6. In another exemplary embodiment, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence. In one embodiment, the SV40 polyadenylation signal sequence comprises or consists of SEQ ID NO:7.

[0073] AAV Capsid: In another aspect, the present application provides a recombinant adeno-associated virus (rAAV) useful as a drug for gene therapy in the treatment of WD, wherein the rAAV comprises an AAV capsid and a vector genome as described herein. In some embodiments, the AAV capsid is derived from serotype 9, 8, 1, 2, 3, 4, 5, 6, 7, 10, 11, 12, rh10, or hu37 AAV (i.e., AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAVrh10, or AAVhu37). In exemplary embodiments, the AAV vector is an AAV serotype 9 (AAV9) vector, an AAV9 variant vector, an AAV serotype 8 (AAV8) vector, an AAV serotype 5 (AAV5) vector, or an AAV serotype 2 (AAV2) vector.In certain embodiments, the AAV capsid and vector are derived from the AAV9 serotype.In certain embodiments, the AAV capsid and vector are derived from the AAV8 serotype.

[0074] The AAV9 capsid is a self-assembled AAV capsid composed of multiple AAV9 VP proteins. The AAV9 VP proteins are typically expressed as alternative splice variants encoding the nucleic acid sequence of SEQ ID NO: 9, which encodes the capsid protein VP1 amino acid sequence of SEQ ID NO: 10 (GenBank Accession: AAS99264), or a sequence that is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% identical to the nucleic acid sequence of SEQ ID NO: 9. These splice variants generate proteins of different lengths of SEQ ID NO: 10. In certain embodiments, the AAV9 capsid comprises an AAV9 capsid protein having an amino acid sequence that is 99% identical to AAS99264 or 99% identical to SEQ ID NO: 10. See also U.S. Patent No. 7,906,111, and International Publication No. WO / 2005 / 033321. As used herein, AAV9 variants include, for example, those described in International Publication No. WO / 2016 / 049230, U.S. Patent No. 8,927,514, U.S. Publication No. 2015 / 0344911, and U.S. Patent No. 8,734,809.

[0075] As shown herein, the AAV9 capsid sequence and capsid protein encoded by the above sequence (e.g., the nucleic acid sequence of SEQ ID NO: 9 or the amino acid sequence of SEQ ID NO: 10 encoding the AAV9 capsid protein VP1) are useful in generating rAAV. However, in other embodiments, another AAV capsid is selected. Tissue specificity is determined by the capsid type. An AAV serotype that transduces an appropriate target (e.g., liver, muscle, lung, or CNS) can be selected as the source of capsid for AAV viral vectors, including, for example, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV6.2, AAV7, AAV8, AAV9, AAVrhlO, AAVrh64Rl, AAVrh64R2, AAVrh8. See, for example, US Patent Publication No. 2007 / 0036760; US Patent Publication No. 2009 / 0197338; and EP1310571. See also International Publication No. WO 2003 / 042397 (AAV7 and other simian AAVs), US Patent No. 7,282,199 and US Patent No. 7,790,449 (AAV8). In addition, AAVs not yet discovered, or recombinant AAVs based thereon, can be used as the source of AAV capsid. These documents also describe other AAVs that can be selected to generate AAV, and are incorporated by reference. In some embodiments, the AAV capsid for use in the viral vector can be generated by mutagenesis (i.e., by insertion, deletion, or substitution) of one of the aforementioned AAV capsids or its encoding nucleic acid.

[0076] Host Cells Containing Recombinant Nucleic Acid Molecules In some aspects, provided herein is a host cell comprising a recombinant nucleic acid molecule, a viral vector, such as an AAV vector, or a rAAV as disclosed herein. In a specific embodiment, the host cell can be suitable for the propagation of AAV.

[0077] A wide range of host cells can be used (e.g., bacterial, yeast, insect, mammalian cells, etc.). In some embodiments, the host cell can be a cell (or cell line) suitable for producing recombinant AAV (rAAV), such as a HeLa, Cos-7, HEK293, A549, BHK, Vero, RD, HT-1080, ARPE-19, or MRC-5 cell. In certain embodiments, the host cell line of the present invention is a HeLa cell line (e.g., HeLa S3). In another embodiment, the host cell line of the present invention is a HEK293 cell line.

[0078] The recombinant nucleic acid molecule or vector can be delivered to host cell culture using any suitable method known in the art. In some embodiments, a suitable host cell line is generated with the recombinant nucleic acid molecule or vector inserted into its genome. In some embodiments, a stable host cell line is generated that contains the AAV vector described herein. After transfection of the AAV vector into the host culture, the integration of the rAAV into the host genome can be assayed by various methods (e.g., antibiotic selection, fluorescence-activated cell sorting, Southern blot, PCR-based detection, fluorescence in situ hybridization), as described by Nakai et al., Nature Genetics (2003) 34:297-302; Philpott et al., Journal of Virology (2002) 76(11):5411-5421, and Howden et al., J. Gene Med. (2008) 10:42-50. Additionally, stable cell lines can be generated using protocols well known in the art (e.g., Clark, Kidney International Vol. 61 (2002):S9-S15, and Yuan et al., Human Gene Therapy, vol. 13, no. 1, 2002). (2011) 22(5):613-24).

[0079] Recombinant AAV for gene therapy: Adeno-associated viruses (AAV) belong to the family Parvoviridae and the genus Dependovirus. AAV is a small, non-enveloped virus that packages a linear, single-stranded DNA genome. Both the sense and antisense strands of AAV DNA are packaged into the AAV capsid with equal frequency.

[0080] The AAV genome is characterized by two inverted terminal repeats (ITRs) flanking two open reading frames (ORFs). The first 125 nucleotides of the AAV2 genome, for example, the ITRs, are palindromic, which fold back on themselves to maximize base pairing, forming a T-shaped hairpin structure. The other 20 bases of the ITRs (referred to as D-sequences) remain unpaired. The ITRs are cis-acting sequences important for AAV DNA replication; they are the origin of replication and act as a primer for second strand synthesis by DNA polymerase. The double-stranded DNA formed during this synthesis (referred to as replicative monomers) is used for a second round of self-priming replication, forming replicative dimers. These double-stranded intermediates are processed via a strand displacement mechanism, resulting in single-stranded DNA used for packaging and double-stranded DNA used for transcription. Rep binding elements and terminal separation sites (TRSs) are located within the ITRs. These features are used by the viral regulatory protein Rep during AAV replication to process double-stranded intermediates. In addition to their role in AAV replication, the ITRs are also essential for AAV genome packaging, transcription, negative regulation under non-permissive conditions, and site-specific integration (Days and Berns, Clin. Microbiol. Rev. (2008) 21(4):583-593).

[0081] The left ORF of AAV contains the Rep gene, which encodes four proteins - Rep78, Rep68, Rep52 and Rep40. The right ORF contains the Cap gene, which generates three viral capsid proteins (VP1, VP2 and VP3). The AAV capsid contains 60 viral capsid proteins arranged into an icosahedral symmetry. VP1, VP2 and VP3 are present in a 1:1:10 molar ratio (Daya et al., 2003). and Berns, Clin. Microbiol. Rev. (2008) 21(4):583-593).

[0082] AAV is currently one of the most frequently used viruses for gene therapy.Although AAV infects humans and several other primate species, it is not known to cause disease and induces very mild immune response.The gene therapy vector that utilizes AAV can infect both dividing and resting cells, and persists in an extrachromosomal state without being integrated into the genome of host cell.Due to the advantageous characteristics of AAV, the present disclosure contemplates the use of AAV for the recombinant nucleic acid molecule and method disclosed herein.

[0083] AAV has some desirable characteristics of gene therapy vectors, including the ability to bind to, enter, and enter the nucleus of target cells, the ability to be expressed in the nucleus for a long period of time, and low toxicity.However, the small size of the AAV genome limits the size of the heterologous DNA that can be integrated.To minimize this problem, AAV vectors that do not code for Rep and integration efficiency element (IEE) have been constructed.The ITRs are retained because they are the cis signals required for packaging (Daya and Berns, Clin. Microbiol. Rev. (2008) 21(4):583-593).

[0084] Methods for generating rAAV suitable for gene therapy are well known in the art (see, e.g., U.S. Patent Application Publication Nos. 2012 / 0100606; 2012 / 0135515; 2011 / 0229971; and 2013 / 0072548; and Ghosh et al., Gene Ther. (2006) 13(4):321-329), and can be utilized with the recombinant nucleic acid molecules and methods disclosed herein.

[0085] In some aspects, the present application relates to the use of the rAAV disclosed herein for the treatment of Wilson's disease (WD), wherein the rAAV comprises an AAV capsid and a vector genome packaged therein. In some embodiments, the vector comprises a genome comprising, as operably linked components, in the order of 5' to 3': a 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a coding sequence of truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1 or SEQ ID NO: 15), and a 3'-inverted terminal repeat (ITR) sequence. In an exemplary embodiment, the vector genome also comprises an enhancer sequence upstream of the promoter sequence, an intron downstream of the promoter, and a polyadenylation sequence upstream of the 3'-ITR. Thus, in another exemplary embodiment, the vector genome comprises, in the order of 5' to 3', a 5'-inverted terminal repeat (ITR) sequence, an enhancer sequence, a promoter sequence, an intron sequence, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1 or SEQ ID NO: 15), a polyadenylation signal sequence, and a 3'-inverted terminal repeat (ITR) sequence as operably linked components. In a further exemplary embodiment, the vector genome comprises, in the order of 5' to 3', an AAV2 5'-ITR sequence, an enTTR enhancer, a TTR promoter, an SV40 Small T intron, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1 or SEQ ID NO: 15), a SV40 polyadenylation signal sequence, and an AAV2 3'-ITR as operably linked components. In some embodiments, the vector genome further comprises a consensus Kozak sequence located downstream of the intron sequence. In some embodiments, the capsid is an AAV9 capsid.

[0086] In some aspects, the present application relates to the use of the rAAV disclosed herein for the treatment of Wilson's disease (WD), wherein the rAAV comprises an AAV capsid and a vector genome packaged therein. In some embodiments, the vector genome comprises, as operably linked components, in the order of 5' to 3': a 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a coding sequence of truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1), and a 3'-inverted terminal repeat (ITR) sequence. In an exemplary embodiment, the vector genome also comprises an enhancer sequence upstream of the promoter sequence, an intron downstream of the promoter, and a polyadenylation sequence upstream of the 3'-ITR. Thus, in another exemplary embodiment, the vector comprises a genome comprising, as operably linked components, in the order of 5' to 3': a 5'-inverted terminal repeat (ITR) sequence, an enhancer sequence, a promoter sequence, an intron sequence, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1), a polyadenylation signal sequence, and a 3'-inverted terminal repeat (ITR) sequence. In a further exemplary embodiment, the vector comprises a genome comprising, as operably linked components, in the order of 5' to 3': an AAV2 5'-ITR sequence, an enTTR enhancer, a TTR promoter, an SV40 Small T intron, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 1), an SV40 polyadenylation signal sequence, and an AAV2 3'-ITR. In some embodiments, the packaged genome further comprises a consensus Kozak sequence located downstream of the intron sequence. In some embodiments, the capsid is an AAV9 capsid.

[0087] In some aspects, the present application relates to the use of the rAAV disclosed herein for the treatment of Wilson's disease (WD), wherein the rAAV comprises an AAV capsid and a packaged vector genome. In some embodiments, the vector comprises a packaged genome comprising, as operably linked components, in the order of 5' to 3': a 5'-inverted terminal repeat (ITR) sequence, a promoter sequence, a coding sequence of truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 15), and a 3'-inverted terminal repeat (ITR) sequence. In an exemplary embodiment, the packaged genome also comprises an enhancer sequence upstream of the promoter sequence, an intron downstream of the promoter, and a polyadenylation sequence upstream of the 3'-ITR. Thus, in another exemplary embodiment, the vector comprises a packaged genome that includes, as operably linked components, in 5' to 3' order: a 5'-inverted terminal repeat (ITR) sequence, an enhancer sequence, a promoter sequence, an intron sequence, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 15), a polyadenylation signal sequence, and a 3'-inverted terminal repeat (ITR) sequence. In a further exemplary embodiment, the vector comprises, as operably linked components, in 5' to 3' order: AAV2 The packaged genome includes a 5'-ITR sequence, an enTTR enhancer, a TTR promoter, an SV40 Small T intron, a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 15), an SV40 polyadenylation signal sequence, and an AAV2 3'-ITR. In some embodiments, the packaged genome further includes a consensus Kozak sequence located downstream of the intron sequence. In some embodiments, the capsid is an AAV9 capsid.

[0088] An exemplary diagram showing an exemplary packaged vector genome construct for expression of a truncated ATP7B retaining MBDs 4, 5, and 6 is provided in Figure 1. The 5'-ITR is represented by nucleotides 1-145; the enTTR enhancer is represented by nucleotides 146-245; the TTR promoter is represented by nucleotides 246-435; the SV40 Small T intron is represented by nucleotides 436-530; the consensus Kozak sequence is represented by nucleotides 531-536; the truncated ATP7B coding sequence is represented by nucleotides 540-4142; the SV40 polyadenylation signal sequence is represented by nucleotides 4143-4340; and the 3'-ITR is represented by nucleotides 4341-4485.

[0089] In certain embodiments, the nucleic acid sequence encoding ATP7B Δ1-3-SS is the native human sequence (represented by SEQ ID NO: 1). Alternatively, in some embodiments, the nucleic acid sequence encoding ATP7B Δ1-3-SS is a codon-optimized human sequence (represented by SEQ ID NO: 15).

[0090] Improved efficacy in treating WD: In certain embodiments, the truncated human ATP7B (ATP7B Δ1-3-SS) encoded by SEQ ID NO:1 or SEQ ID NO:15 described herein is more effective than the full length or other truncated forms of ATP7B (e.g., ATP7B Δ1-4, SEQ ID NO:13). In some aspects, the ATP7B Δ1-3-SS of the present disclosure is localized to the trans-Golgi network (TGN). In certain embodiments, a rAAV comprising the nucleic acid sequence of SEQ ID NO:1 and encoding ATP7B Δ1-3-SS, when injected into a mammal diagnosed with a copper metabolism disorder (e.g., Wilson's disease), reduces copper levels in the liver and urine of the mammal.

[0091] Improved yields of AAV vectors containing truncated ATP7B: In one aspect, a rAAV comprising a nucleic acid sequence encoding ATP7B Δ1-3-SS packaged into AAV8 or AAV9 as described herein has a production yield that is about 1.1 to about 10-fold (e.g., about 1.1-fold, about 1.2-fold, about 1.3-fold, about 1.4-fold, about 1.5-fold, about 1.6-fold, about 1.7-fold, about 1.8-fold, about 1.9-fold, about 2-fold, about 3-fold, about 4-fold, about 5-fold, about 6-fold, about 7-fold, about 8-fold, about 9-fold, or about 10-fold) higher than that of full-length ATP7B or ATP7B Δ1-4.

[0092] Improved yields of AAV vectors containing AAV9 capsids: In one aspect, a rAAV containing the AAV9 capsid has a titer yield that is about 1.1 to about 10 times (e.g., about 1.1 times, about 1.2 times, about 1.3 times, about 1.4 times, about 1.5 times, about 1.6 times, about 1.7 times, about 1.8 times, about 1.9 times, about 2 times, about 3 times, about 4 times, about 5 times, about 6 times, about 7 times, about 8 times, about 9 times, or about 10 times) higher than a rAAV containing the AAV8 capsid.

[0093] Pharmaceutical Compositions: The present disclosure provides a composition comprising the rAAV disclosed herein and a pharma- ceutically acceptable carrier.Appropriate pharmaceutical formulations for administration of rAAV can be found, for example, in US Patent Application Publication 2012 / 0219528.The pharma- ceutically acceptable carrier (vehicle) useful in the present disclosure is conventional.Remington's Pharmaceutical Sciences by EW Martin (Mack Publishing Co., Easton, Pa., 15th Edition (1975)) describes compositions and formulations suitable for pharmaceutical delivery of one or more therapeutic compounds, molecules or agents.

[0094] As highlighted in the previous paragraph, the present application relates in some aspects to a pharmaceutical composition comprising the rAAV of the present invention. In some embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable carrier or excipient. In some embodiments, the pharmaceutical composition is formulated for subcutaneous, intramuscular, intradermal, intraperitoneal, or intravenous administration. In an exemplary embodiment, the pharmaceutical composition is formulated for intravenous administration.

[0095] In some embodiments, the rAAV is formulated in a buffer / carrier suitable for injection in a human subject. The buffer / carrier should contain components that prevent the rAAV from sticking to the injection tubing but do not interfere with rAAV binding activity in vivo. A variety of suitable solutions may include one or more of the following: a buffered saline solution, a surfactant, and a physiologically compatible salt or mixture of salts adjusted to an ionic strength equivalent to about 100 mM sodium chloride (NaCl) to about 250 mM sodium chloride, or a physiologically compatible salt adjusted to an equivalent ionic concentration. The pH may be in the range of 6.5 to 8.5, or 7 to 8.5, or 7.5 to 8. Suitable surfactants or surfactant combinations may be selected from poloxamers, i.e. non-ionic triblock copolymers composed of a central hydrophobic chain of polyoxypropylene 10 (poly(propylene oxide)) flanked by two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)), SOLUTOL HS 15 (macrogol-15 hydroxystearate), LABRASOL (polyoxycaprylic acid glyceride), polyoxy 10 oleyl ether, TWEEN® (polyoxyethylene sorbitan fatty acid esters), ethanol and polyethylene glycol.

[0096] How to treat Wilson's disease: In yet another aspect, the present application relates to a method of treating WD in a human subject, comprising administering to the human subject a therapeutically effective amount of an rAAV comprising SEQ ID NO:1 or SEQ ID NO:15, as disclosed herein, encoding truncated ATP7B (ATP7B Δ1-3-SS).

[0097] In one embodiment, the application provides a method of treating WD, comprising administering a rAAV comprising an AAV capsid and a packaged vector genome, wherein the vector genome comprises a coding sequence for truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO:1 or SEQ ID NO:15).

[0098] In yet another aspect, the present application relates to a method for treating WD in a human subject, comprising administering to a human subject diagnosed with at least one mutation in ATP7B a therapeutically effective amount of at least one rAAV comprising a vector genome comprising a coding sequence (e.g., SEQ ID NO: 1 or SEQ ID NO: 15) of truncated human ATP7B (ATP7B Δ1-3-SS). In one embodiment, the present application provides a method for treating WD in a human subject diagnosed with at least one mutation in ATP7B, comprising administering a rAAV comprising an AAV capsid and a packaged vector genome, wherein the vector genome comprises a coding sequence (e.g., SEQ ID NO: 1 or SEQ ID NO: 15) of truncated human ATP7B (ATP7B Δ1-3-SS). The coding sequence as represented by SEQ ID NO: 1 encodes the truncated ATP7B represented by SEQ ID NO: 8. In some embodiments, the capsid is an AAV9 capsid.

[0099] In yet another aspect, the present application relates to a method for treating WD in a human subject, comprising administering to a human subject diagnosed with at least one mutation in ATP7B a therapeutically effective amount of at least one rAAV comprising a vector genome comprising a coding sequence (e.g., SEQ ID NO: 1) of truncated human ATP7B (ATP7B Δ1-3-SS). In one embodiment, the present application provides a method for treating WD in a human subject diagnosed with at least one mutation in ATP7B, comprising administering a rAAV comprising an AAV capsid and a packaged vector genome, wherein the vector genome comprises a coding sequence (e.g., SEQ ID NO: 1) of truncated human ATP7B (ATP7B Δ1-3-SS). The coding sequence as represented by SEQ ID NO: 1 encodes the truncated ATP7B represented by SEQ ID NO: 8. In some embodiments, the capsid is an AAV9 capsid.

[0100] In yet another aspect, the present application relates to a method of treating WD in a human subject, comprising administering to a human subject diagnosed with at least one mutation in ATP7B a therapeutically effective amount of at least one rAAV comprising a vector genome comprising a coding sequence of truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 15). In one embodiment, the present application provides a method of treating WD in a human subject diagnosed with at least one mutation in ATP7B, comprising administering a rAAV comprising an AAV capsid and a packaged vector genome, wherein the vector genome comprises a coding sequence of truncated human ATP7B (ATP7B Δ1-3-SS) (e.g., SEQ ID NO: 15). In some embodiments, the capsid is an AAV9 capsid.

[0101] Any suitable method or route can be used to administer rAAV or rAAV-containing compositions described herein.Administration routes include, for example, systemic, oral, inhalation, intranasal, intratracheal, intraarterial, intraocular, intravenous, intramuscular, subcutaneous, intradermal, and other parenteral routes.In some embodiments, the rAAV or rAAV-containing compositions are administered intravenously.

[0102] The specific dose administered is a uniform dose for each patient, e.g., 1.0×10 11 ~1.0×10 14 The dose may be in viral genomes (vg) / kg. Alternatively, the patient dose may be adjusted to the approximate body weight or surface area of ​​the patient. Other factors in determining the appropriate dosage may include the disease or condition to be treated or prevented, the severity of the disease, the route of administration, and the age, sex, and medical condition of the patient. Further refinement of the calculations required to determine the appropriate dosage for treatment is routinely performed by those skilled in the art, especially in light of the dosage information and assays disclosed herein. The dosage may also be determined through the use of known assays to determine the dosage to be used with appropriate dose-response data. The dosage for an individual patient may also be adjusted as the progression of the disease is monitored.

[0103] In some embodiments, the rAAV is expressed as, for example, about 1.0×10 11 vg / kg ~ approx. 1×10 14 vg / kg, approx. 5×10 11 vg / kg ~ approx. 5×10 13 vg / kg, or approximately 1 × 10 12 ~Approx. 1×10 13 In some embodiments, the rAAV is administered at a dose of about 2×10 12 In some embodiments, the rAAV is administered at a dose of about 5×10 12In some embodiments, the rAAV is administered at a dose of about 6×10 12 In some embodiments, the rAAV is administered at a dose of about 1×10 13 In some embodiments, the rAAV is administered at a dose of about 7×10 13 The rAAV is administered in a dose of 1000 mg / kg vg / kg. The rAAV may be administered in a single dose, or in multiple doses (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses) if required for the desired therapeutic outcome. In some exemplary embodiments, only a single dose of a particular rAAV is administered.

[0104] Throughout the detailed description, when compositions are described as having, including, or comprising particular components, or when processes and methods are described as having, including, or comprising particular steps, it is further contemplated that there are compositions of the invention that consist essentially of or consist of the recited components, and that there are processes and methods according to the invention that consist essentially of or consist of the recited processing steps.

[0105] In this application, when an element or component is referred to as being included in and / or selected from a list of described elements or components, it is to be understood that the element or component can be any one of the described elements or components, or that the element or component can be selected from a group consisting of two or more of the described elements or components.

[0106] Furthermore, it should be understood that the elements and / or features of the compositions or methods described herein, whether express or implied herein, can be combined in various ways without departing from the spirit and scope of the present invention.For example, when a reference is made to a particular compound, that compound can be used in various embodiments of the compositions of the present invention and / or in the methods of the present invention, unless otherwise understood from the context.In other words, in this application, the embodiments are described and shown in a manner that allows a clear and concise application to be written and depicted, but it is intended and recognized that the embodiments can be variously combined or separated without being separated from the present teachings and the present invention.For example, it is recognized that all features described and shown herein can be applicable to all aspects of the invention described and shown herein.

[0107] The phrase "at least one of" should be understood to include each of the listed objects that follow the phrase, and two or more various embodiments of that listed object, individually, unless otherwise understood from context and use. In the context of three or more listed objects, the phrase "and / or" should be understood to have the same meaning, unless otherwise understood from context.

[0108] Use of the terms "include," "includes," "including," "have," "having," "contain," "contains," or "containing," including grammatical equivalents thereof, should generally be understood to be open-ended and non-limiting, e.g., not excluding additional, unrecited elements or steps unless otherwise specifically stated or understood from the context.

[0109] When the term "about" is used before a quantitative value, the present invention also includes the particular quantitative value itself, unless specifically stated otherwise. As used herein, the term "about" refers to a ±10% variation from the nominal value, unless otherwise indicated or inferred.

[0110] It should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions may be considered simultaneous.

[0111] Any and all examples or exemplary language, e.g., "such as, for example, The use of "as" or "including" herein is intended merely to better illustrate the invention and does not impose limitations on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention. EXAMPLES

[0112] The invention, generally described herein, will be readily understood by reference to the following examples, which are included solely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention.

[0113] Example 1 - AAV vectors and rAAV generated from these vectors AAV vectors This example describes the construction of an AAV vector having a nucleic acid sequence represented by SEQ ID NO:1 flanked by two AAV2 inverted terminal repeats (ITRs, SEQ ID NO:2). SEQ ID NO:1 represents the cDNA of native human ATP7B with MBDs 1-3 deleted. Nucleotides 223-225 in SEQ ID NO:1 encode a serine residue, S340, and nucleotides 226-228 in SEQ ID NO:1 encode a serine residue, S341 (numbering is based on the wild-type full-length ATP7B protein sequence).

[0114] As depicted in Figure 1, within the AAV vector, the ATP7B expression cassette comprises an enhancer (EnTTR), a promoter (TTR), an intron (SV40 small T intron), the nucleotide sequence of SEQ ID NO: 1 encoding truncated human ATP7B (ATP7B Δ1-3-SS), and the SV40 poly(A) signal. A circular map of the vector illustrating the various components is shown in Figure 2.

[0115] The AAV vector DTC319 contains a truncated human ATP7B sequence in which metal binding domains 4, 5, and 6 are retained. The truncated human ATP7B sequence is represented by SEQ ID NO:8 and encodes a protein that contains two serine residues, S340 and S341 (numbered according to NCBI Reference Sequence: NP_000044.2).

[0116] The Simian Virus 40 (SV40) late polyadenylation signal (Genbank Accession No. J02400 (SEQ ID NO: 7)) provides a cis sequence for efficient polyadenylation of ATP7B mRNA. This element functions as a signal for specific cleavage events at the 3' end of the nascent transcript and addition of a long polyadenylation tail.

[0117] Each truncated ATP7B expression cassette was cloned into an AAV vector. All AAV vectors had a backbone encoding a kanamycin resistance gene. An exemplary AAV vector DTC319 is illustrated in Figure 2. Figure 1 shows the expression cassette of DTC319 for expressing ATP7B (ATP7B Δ1-3-SS).

[0118] rAAV virions The AAV vector genome is a single-stranded genome. Only the sequence between and including the ITR sequences is packaged into AAV virions. The virions were generated by transfecting three plasmids into human embryonic kidney 293 (HEK293) cells that provide E1a and E1b gene products. The first plasmid can be the AAV vector disclosed herein. The second plasmid can be a packaging plasmid that contains wild-type AAV2 rep and AAV8 or AAV9 cap genes. The third plasmid is a helper adenovirus plasmid.

[0119] A diagram of an exemplary packaging plasmid, pAAV2 / 8.KanR(p2123FH) plasmid, is shown in FIG. 3. In this plasmid, the adeno-associated Rep / Cap plasmid pAAV2 / 8.KanR(p2123FH) (8354 bp) encodes four wild-type AAV2 viral replication (Rep) proteins and three wild-type AAV VP capsid (cap) proteins from serotype 8. Within the plasmid, the AAV p5 promoter, which normally drives Rep gene expression, has been moved from the 5' end of the Rep region to the 3' end of the AAV8 cap region. This arrangement introduces a spacer between the promoter and the Rep gene (i.e., the plasmid backbone), resulting in downregulation of Rep expression and increased ability to support high-titer rAAV production. A gene for kanamycin resistance and an MB1 origin are included for plasmid production in E. coli.

[0120] A diagram of an exemplary helper plasmid, pAdDeltaF6(Kan), is shown in Figure 4. In this plasmid, regions of the adenovirus genome important for AAV replication, namely E2A, E4, and VA RNA are provided. Adenovirus E1 functions are also required, but are provided by the HEK293 host cell. Because the plasmid shown in Figure 4 does not contain other adenovirus replication, structural genes, or cis elements critical for adenovirus replication (e.g., adenovirus ITRs), infectious adenovirus is not expected to be generated. A gene for kanamycin resistance and an MB1 origin are included for plasmid production in E. coli.

[0121] Example 2 - Deletion of metal binding domains (MBD) 1-3 in human ATP7B improves manufacturing yield This example describes experiments which demonstrated that ATP7B Δ1-3-SS had higher yields than either full-length ATP7B or the truncated form ATP7B Δ1-4.

[0122] Lack of functional ATP7B results in accumulation of copper in the liver and other tissues, manifesting as liver disease with neurological or psychiatric symptoms. WD can be treated by reducing copper absorption from the body or by removing excess copper. C3He-Atp7b tx-j Mice serve as a mouse model of WD because they do not express functional Atp7b. An AAV vector containing the codon-optimized full-length human ATP7B sequence was used to transfect HEK293 cells with a Rep / Cap plasmid encoding four wild-type AAV2 viral replication (Rep) proteins and three wild-type AAV VP capsid (cap) proteins from serotype 8 and a helper plasmid to obtain ATP7BcoFL viral particles.

[0123] Male C3He-Atp7b tx-j Mouse, 10 10 GC / kg or 10 11GC / kg of either ATP7BcoFL (codon-optimized full-length human ATP7B) was injected intravenously (iv). tx-j Mouse, 10 9 GC / kg, 10 10 GC / kg, or 10 11 Hepatic copper levels in male (indicated by squares) and female (indicated by circles) mice were assessed by inductively coupled plasma mass spectrometry (ICP-MS) and age-matched uninjected male and female heterozygous (Het) mice and C3He-Atp7b mice were injected iv with either C3He-Atp7b or C3He-Atp7b GC / kg. tx-j The copper levels of the mice were compared. The mice were necropsied at approximately 9 months of age and the livers were harvested. The data are shown in Figure 5.

[0124] Gene therapy utilizing AAV vectors can be used to treat WD. However, there is a limit to the size of cDNA that can be packaged inside the AAV vector capsid. The wild-type AAV genome is 4.7 kb, and packaging a larger genome could potentially reduce the yield and integrity of the DNA sequence encapsulated in the AAV capsid. Therefore, a nucleotide sequence encoding ATP7B Δ1-3-SS was packaged into AAV8 capsids and the production yield of ATP7B Δ1-3-SS was tested. AAV vectors encoding either full-length (FL) human ATP7B, human ATP7B with MBDs 1-3 deleted but with a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4 (ATP7B Δ1-3-SS), or human ATP7B with MBDs 1-4 deleted (ATP7B Δ1-4) were transfected into HEK293 cells. A Rep / Cap plasmid encoding four wild-type AAV2 viral replication (Rep) proteins and three wild-type AAV VP capsid (cap) proteins from serotype 8, and a helper plasmid were co-transfected with AAV vectors expressing various ATP7B proteins. Figure 6 is a bar graph showing titration of rAAV produced from host cells after transfection of various AAV vectors. The Y-axis shows the total yield of each rAAV titration in genome copies (GC). The data show that ATP7B Δ1-3-SS had a higher yield than either the full-length or ATP7B Δ1-4 truncated forms.

[0125] Example 3 - ATP7B Δ1-3-SS is more effective at restoring copper metabolism compared to ATP7B FL This example shows C3He-Atp7b tx-j We describe experiments demonstrating that ATP7B Δ1-3-SS is more effective than ATP7B full-length (ATP7B FL) or ATP7B Δ1-4 in restoring copper metabolism in mice.

[0126] As described in Example 2 above, packaging bulky cDNA sequences into AAV vector capsids may reduce the integrity of the DNA sequences and may have potential quality issues. Therefore, truncated versions of human ATP7B were packaged into AAV8 capsids to test their effectiveness in restoring copper metabolism. 1.0×10 6 AAV8 vectors containing either full-length or truncated human ATP7B were packaged into AAV8 capsids to test their effectiveness in restoring copper metabolism. 13 GC / kg, C3He-Atp7b tx-j Mice were administered 100 mg of C3He-Atp7b. Liver and urinary copper levels were assessed by inductively coupled plasma mass spectrometry. tx-j Scatter plots (squares and circles, respectively) of urinary and hepatic copper levels assayed after injecting mice with AAV8 carrying full-length human ATP7B (ATP7B FL), ATP7B Δ1-3-SS, or ATP7B Δ1-4 (μg / g). tx-j We show that C3He-Atp7b is more effective than ATP7B full length (ATP7B FL) or ATP7B Δ1-4 in restoring copper metabolism in mice. tx-j Mice served as controls (vehicle).

[0127] Example 4 - AAV vectors containing AAV9 capsids showed higher virus production This example describes an experiment that showed that the production of AAV vectors containing AAV9 capsids produces higher yields in comparison to the production of AAV vectors containing AAV8 capsids. The different AAV vectors were titrated by qPCR quantifying DNase-resistant particles (DRPs). Figure 8 shows the total yields (titrated in genome copies (GC)) of rAAV produced from host cells after transfection with an AAV vector (DTC319) encoding a truncated human ATP7B in which metal-binding domains (MBDs) 1-3 are deleted but a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4 is present, and co-transfection with plasmids encoding either AAV8 capsids or AAV9 capsids.

[0128] Example 5 - Therapeutic properties of ATP7B Δ1-3-SS This example shows the mouse model (C3He-Atp7b tx-j We describe animal studies that have shown the efficacy of ATP7B Δ1-3-SS (e.g., DTC319, an rAAV vector encoding a truncated human ATP7B lacking metal binding domains (MBDs) 1-3 but with a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4) in improving Wilson's disease (WD) symptoms and treating WD in mice (C3He-Atp7b tx-j Mice), and wild-type (WT) mice served as negative controls. For injections, rAAV was produced by triple transient transfection of adherent HEK cells and purified by cesium chloride gradient ultracentrifugation, a purification method well known in the art. At the study endpoint, 4 weeks after injection, mice from each group were evaluated for hepatic tract accumulation, ceruloplasmin activity, and liver pathology.

[0129] Hepatic copper accumulation was measured by inductively coupled plasma mass spectrometry (ICP-MS) and showed that hepatic copper levels were significantly reduced in WD mice administered ATP7B Δ1-3-SS (e.g., DTC319) compared to vehicle controls (see FIG. 9, DelA bars). FIG. 9 shows the hepatic copper accumulation in WD mice administered C3He-Atp7b Δ1-3-SS (e.g., DTC319) after intravenous injection of vehicle control (dilution buffer, WD bars) or AAV8 with native ATP7B Δ1-3-SS (DelA bars). tx-j Figure 1 shows liver copper accumulation levels (μg / g) in mice. Liver copper accumulation levels in uninjected wild-type mice (WT) served as negative controls, as shown in the bar graph. Values ​​are expressed as mean ± SEM.

[0130] Ceruloplasmin activity was significantly increased in WD mice after administration of ATP7B Δ1-3-SS (e.g., DTC319) (see FIG. 10, DelA bar). Ceruloplasmin activity was detected using an enzyme reaction-based colorimetric activity assay well known in the art (see Schosinsky et al., Clin Chem. 1974; 20(12):1556-63). FIG. 10 shows the increase in ceruloplasmin activity in WD mice after intravenous injection of vehicle control (dilution buffer, WD bar) or AAV injection of ATP7B Δ1-3-SS encoded in AAV8 vector (DelA bar), as shown by enzyme reaction-based colorimetric activity assay. tx-j Figure 1 shows ceruloplasmin activity in mice. Ceruloplasmin activity of uninjected wild type (WT) mice is also shown in a bar graph as shown by enzyme reaction-based colorimetric activity assay. The plot shows the activity of ceruloplasmin as measured in optical density, OD, as read at 540 nm. Values ​​are expressed as mean ± SEM.

[0131] Livers were harvested from all animals in each group and stained with H&E (hematoxylin and eosin staining). H&E slides were evaluated by a board certified pathologist according to a scoring system of 0 to 4 for nuclear enlargement and hepatocellular hypertrophy, tissue disruption, inflammatory infiltration, and hepatocellular necrosis. Scores from each mouse in the group were averaged. Figure 11 shows the average scores obtained after standard evaluation of H&E slides of animals in each group.

[0132] Example 6 - AAV9 Gene Therapy as a Viable Treatment for Wilson's Disease (WD) This example describes the use of rAAV particles containing ATP7B Δ1-3-SS in treating WD in a subject. An AAV vector containing a nucleotide sequence encoding truncated human ATP7B (ATP7B Δ1-3-SS), e.g. DTC319 (FIG. 2), a Rep / Cap plasmid encoding four wild-type AAV2 viral replication (Rep) proteins and three wild-type AAV VP capsid (cap) proteins from serotype 9 (AAV9), and a helper plasmid are co-transfected into host cells as described in Example 1. The harvested rAAV particles are then administered intravenously to a subject in need of WD treatment. Alternatively, a subject is administered rAAV particles harvested from host cells transfected with a vector represented by FIG. 12 to treat WD.

[0133] References The entire disclosures of each of the patent documents and scientific articles referred to herein are incorporated by reference for all purposes.

[0134] Equivalent The present disclosure may be embodied in other specific forms without departing from its spirit and essential characteristics. Therefore, the foregoing embodiments should be considered in all respects as illustrative rather than limiting of the disclosure described herein. The various structural elements of the different embodiments and the steps of the various disclosed methods may be utilized in various combinations and permutations, and all such modifications should be considered as forms of the present disclosure. The scope of the present disclosure is therefore indicated by the appended claims, rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein. In certain embodiments, for example, the following items are provided: (Item 1) 1. A recombinant nucleic acid construct comprising: (a) 5′-inverted terminal repeat (ITR); (b) promoter sequence; (c) a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) lacking metal-binding domains (MBDs) 1-3 but containing a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4; and (d) 3'-ITR sequence A recombinant nucleic acid construct comprising: (Item 2) 2. The recombinant nucleic acid construct of item 1, wherein the promoter is selected from the group consisting of a transthyretin (TTR) promoter, a chicken beta-actin (CBA) promoter, a cytomegalovirus immediate early gene (CMV) promoter, a thyroxine-binding globulin (TBG) promoter, an alpha 1 antitrypsin (A1AT) promoter, and a CAG promoter. (Item 3) 3. The recombinant nucleic acid construct of claim 2, wherein the promoter is the TTR promoter. (Item 4) 4. The recombinant nucleic acid construct according to any one of items 1 to 3, wherein the 5'-ITR sequence is derived from AAV2. (Item 5) 4. The recombinant nucleic acid construct according to any one of items 1 to 3, wherein the 3'-ITR sequence is derived from AAV2. (Item 6) 4. The recombinant nucleic acid construct according to any one of items 1 to 3, wherein the 5'-ITR sequence and the 3'-ITR sequence are derived from AAV2. (Item 7) 7. The recombinant nucleic acid construct according to any one of items 1 to 6, wherein the 5'-ITR sequence and the 3'-ITR sequence comprise or consist of SEQ ID NO:2. (Item 8) 4. The recombinant nucleic acid construct according to any one of items 1 to 3, wherein the 5'-ITR sequence and / or the 3'-ITR sequence is derived from a non-AAV2 source. (Item 9) 9. The recombinant nucleic acid construct according to any one of items 1 to 8, wherein the recombinant nucleic acid construct further comprises one or more enhancer sequences. (Item 10) 10. The recombinant nucleic acid construct of item 9, wherein the enhancer is selected from a transthyretin enhancer (enTTR), a cytomegalovirus immediate early gene (CMV) enhancer, a chicken beta-actin (CBA) enhancer, an En34 enhancer, and an apolipoprotein (ApoE) enhancer. (Item 11) 11. The recombinant nucleic acid construct of item 10, wherein the enhancer is the enTTR enhancer. (Item 12) 12. The recombinant nucleic acid construct of item 11, wherein the enhancer comprises or consists of SEQ ID NO:3. (Item 13) 13. The recombinant nucleic acid construct according to any one of items 10 to 12, wherein the enhancer is located upstream of the promoter sequence. (Item 14) 14. The recombinant nucleic acid construct according to any one of items 1 to 13, wherein the recombinant nucleic acid construct further comprises one or more intron sequences. (Item 15) 15. The recombinant nucleic acid construct of item 14, wherein the intron is selected from the group consisting of an SV40 Small T intron, a rabbit hemoglobin subunit beta (rHBB) intron, a human beta globin IVS2 intron, a Promega chimeric intron, and an hFIX intron. (Item 16) 16. The recombinant nucleic acid construct of claim 15, wherein the intron is the SV40 Small T intron. (Item 17) 17. The recombinant nucleic acid construct according to item 16, wherein the intron comprises or consists of SEQ ID NO:4. (Item 18) 16. The recombinant nucleic acid construct of claim 15, wherein the intron is the rHBB intron. (Item 19) 19. The recombinant nucleic acid construct according to item 18, wherein the intron comprises or consists of SEQ ID NO:5. (Item 20) 20. The recombinant nucleic acid construct according to any one of items 1 to 19, further comprising a polyadenylation signal sequence. (Item 21) 21. The recombinant nucleic acid construct of item 20, wherein the polyadenylation signal sequence is selected from the group consisting of an SV40 polyadenylation signal sequence, a bovine growth hormone (BGH) polyadenylation signal sequence, and a rabbit beta globin polyadenylation signal sequence. (Item 22) 22. The recombinant nucleic acid construct of claim 21, wherein the polyadenylation signal sequence is the bovine growth hormone (BGH) polyadenylation signal sequence. (Item 23) 23. The recombinant nucleic acid construct according to item 22, wherein the polyadenylation signal sequence comprises or consists of SEQ ID NO:6. (Item 24) 22. The recombinant nucleic acid construct of claim 21, wherein the polyadenylation signal sequence is the SV40 polyadenylation signal sequence. (Item 25) 25. The recombinant nucleic acid construct according to item 24, wherein the polyadenylation signal sequence comprises or consists of SEQ ID NO:7. (Item 26) A recombinant adeno-associated virus (rAAV) useful for the treatment of Wilson's disease, said rAAV comprising an AAV capsid and a vector genome packaged therein, said vector genome comprising: AAV 5'-inverted terminal repeat (ITR) sequence; b. promoter / enhancer sequences; c. a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) lacking metal-binding domains (MBD) 1-3 but containing a serine-rich loop containing two serine residues (S340 and S341) between MBD3 and MBD4; and d. AAV 3'-ITR, Including, rAAV. (Item 27) 27. The rAAV of item 26, wherein the AAV capsid is derived from an AAV of serotype 9, 8, 1, 2, 3, 4, 5, 6, 7, 10, 11, 12, rh10, or hu37. (Item 28) 28. The rAAV of item 27, wherein the AAV capsid is derived from AAV9. (Item 29) 28. The rAAV of item 27, wherein the AAV capsid is derived from AAV8. (Item 30) 29. The rAAV of item 28, wherein the AAV capsid is an AAV9 variant capsid. (Item 31) 31. The rAAV according to any one of Items 26 to 30, wherein the promoter is selected from a transthyretin (TTR) promoter, a chicken beta-actin (CBA) promoter, a cytomegalovirus immediate early gene (CMV) promoter, a thyroxine-binding globulin (TBG) promoter, an alpha 1 antitrypsin (A1AT) promoter, and a CAG promoter. (Item 32) 32. The rAAV of claim 31, wherein the promoter is the TTR promoter. (Item 33) 33. The rAAV according to any one of items 26 to 32, wherein the 5'-ITR sequence is derived from AAV2. (Item 34) 33. The rAAV according to any one of items 26 to 32, wherein the 3'-ITR sequence is derived from AAV2. (Item 35) 33. The rAAV according to any of Items 26 to 32, wherein the 5'-ITR sequence and the 3'-ITR sequence are derived from AAV2. (Item 36) 36. The rAAV according to any one of items 26 to 35, wherein the 5'-ITR sequence and the 3'-ITR sequence comprise or consist of SEQ ID NO:2. (Item 37) 33. The rAAV according to any of items 26 to 32, wherein the 5'-ITR sequence and / or the 3'-ITR sequence is derived from a non-AAV2 source. (Item 38) 38. The rAAV of any of items 26 to 37, wherein the packaged genome further comprises one or more enhancer sequences. (Item 39) 39. The rAAV of claim 38, wherein the enhancer is selected from a transthyretin enhancer (enTTR), a cytomegalovirus immediate early gene (CMV) enhancer, a chicken beta-actin (CBA) enhancer, an En34 enhancer, and an apolipoprotein (ApoE) enhancer. (Item 40) The rAAV of item 39, wherein the enhancer is the enTTR enhancer. (Item 41) The rAAV of item 40, wherein the enhancer comprises or consists of SEQ ID NO:3. (Item 42) 42. The rAAV according to Items 40 to 41, wherein the enhancer is located upstream of the promoter sequence. (Item 43) 43. The rAAV of any of items 26 to 42, wherein the packaged genome further comprises one or more intron sequences. (Item 44) 44. The rAAV of item 43, wherein the intron is selected from the group consisting of an SV40 Small T intron, a rabbit hemoglobin subunit beta (rHBB) intron, a human beta globin IVS2 intron, a Promega chimeric intron, and an hFIX intron. (Item 45) 45. The rAAV of item 44, wherein the intron is the SV40 Small T intron. (Item 46) 46. ​​The rAAV of item 45, wherein the intron comprises or consists of SEQ ID NO:4. (Item 47) 45. The rAAV of item 44, wherein the intron is the rHBB intron. (Item 48) 48. The rAAV of item 47, wherein the intron comprises or consists of SEQ ID NO:5. (Item 49) 49. The rAAV according to any one of items 26 to 48, wherein the packaged genome further comprises a polyadenylation signal sequence. (Item 50) 50. The rAAV of item 49, wherein the polyadenylation signal sequence is selected from the group consisting of an SV40 polyadenylation signal sequence, a bovine growth hormone (BGH) polyadenylation signal sequence, and a rabbit beta globin polyadenylation signal sequence. (Item 51) 51. The rAAV of claim 50, wherein the polyadenylation signal sequence is the bovine growth hormone (BGH) polyadenylation signal sequence. (Item 52) 52. The rAAV of item 51, wherein the polyadenylation signal sequence comprises or consists of SEQ ID NO:6. (Item 53) 51. The rAAV of claim 50, wherein the polyadenylation signal sequence is the SV40 polyadenylation signal sequence. (Item 54) 54. The rAAV of item 53, wherein the polyadenylation signal sequence comprises or consists of SEQ ID NO:7. (Item 55) 26. An rAAV comprising the recombinant nucleic acid according to any one of items 1 to 25. (Item 56) 1. A recombinant nucleic acid construct comprising: a. The AAV 5'-inverted terminal repeat (ITR) sequence of SEQ ID NO:2; b. an enhancer sequence of SEQ ID NO:3; c. The promoter sequence of SEQ ID NO: 12; d. a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) of SEQ ID NO:1 or SEQ ID NO:15; and e. AAV 3'-ITR of SEQ ID NO:2; A recombinant nucleic acid construct comprising: (Item 57) 57. The recombinant nucleic acid construct of claim 56, wherein the nucleic acid sequence encoding the truncated human copper-transporting ATPase 2 (ATP7B) is SEQ ID NO: 1. (Item 58) 57. The recombinant nucleic acid construct of claim 56, wherein the nucleic acid sequence encoding the truncated human copper-transporting ATPase 2 (ATP7B) is SEQ ID NO: 15. (Item 59) 1. A rAAV comprising an AAV capsid and a vector genome packaged therein, the vector genome comprising: a. The AAV 5'-inverted terminal repeat (ITR) sequence of SEQ ID NO:2; b. an enhancer sequence of SEQ ID NO:3; c. The promoter sequence of SEQ ID NO: 12; d. a nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) of SEQ ID NO:1 or SEQ ID NO:15; and e. AAV 3'-ITR of SEQ ID NO:2; Including, rAAV. (Item 60) 59. The rAAV of claim 58, wherein the vector genome comprises the nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) of SEQ ID NO: 1. (Item 61) 60. The rAAV of claim 59, wherein the vector genome comprises the nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) of SEQ ID NO: 15. (Item 62) A host cell comprising a recombinant nucleic acid according to any one of items 1 to 25 or 56 to 58, or an rAAV according to any one of items 26 to 55 or 59 to 61. (Item 63) A composition comprising the rAAV according to any one of items 26 to 55 or 59 to 61, and a pharma- ceutically acceptable carrier. (Item 64) 59. A recombinant vector comprising a recombinant nucleic acid molecule according to any one of items 1 to 25 or 56 to 58. (Item 65) 65. The recombinant vector of item 64, wherein the vector is an adeno-associated virus (AAV) vector. (Item 66) 66. The recombinant vector of claim 65, wherein the AAV vector is an AAV serotype 9 (AAV9) vector. (Item 67) 67. A method of increasing rAAV yield for use in treating Wilson's disease, the method comprising delivering a recombinant vector according to any one of claims 64 to 66 to a eukaryotic host cell culture and harvesting the rAAV from the eukaryotic cell culture. (Item 68) A method for treating Wilson's disease in a human subject, the method comprising administering to the human subject a therapeutically effective amount of the rAAV described in any of items 26 to 55 or 59 to 61, or the composition thereof described in item 63. (Item 69) 69. The method of claim 68, wherein the rAAV or composition is administered subcutaneously, intramuscularly, intradermally, intraperitoneally, or intravenously. (Item 70) 70. The method of claim 69, wherein the rAAV or composition is administered intravenously. (Item 71) The rAAV is about 1×10 11 ~Approx. 1×10 14 71. The method of any of items 68 to 70, wherein the method is administered at a dose of genome copies (GC) / kg. (Item 72) The rAAV is about 1×10 12 ~Approx. 1×10 13 72. The method of claim 71, wherein the compound is administered at a dose of 100 mg / kg. (Item 73) 73. The method of any of items 68 to 72, wherein the step of administering rAAV comprises administration of a single dose of rAAV. (Item 74) 73. The method of any of items 68 to 72, wherein the step of administering rAAV comprises administration of multiple doses of rAAV. (Item 75) The recombinant nucleic acid construct according to any of items 1 to 25 or 56 to 58, the rAAV according to any of items 26 to 55 or 59 to 61, the composition according to item 63, the host cell according to item 62, the recombinant vector according to any of items 64 to 66, or the method according to any of items 67 to 74, wherein the nucleic acid sequence encoding a truncated human copper-transporting ATPase 2 (ATP7B) comprises or consists of SEQ ID NO: 1 or SEQ ID NO: 15. (Item 76) A recombinant nucleic acid comprising a nucleic acid sequence which is at least 80% identical to SEQ ID NO:14. (Item 77) 77. The recombinant nucleic acid of item 76, wherein the nucleic acid sequence comprises SEQ ID NO:14.

Claims

1. A recombinant nucleic acid comprising a nucleic acid sequence that is at least 80% identical to SEQ ID NO:

14.

2. The recombinant nucleic acid of claim 1 , wherein the nucleic acid sequence comprises the nucleic acid sequence set forth in SEQ ID NO:

14.

3. The recombinant nucleic acid of claim 2, wherein the nucleic acid sequence consists of the nucleic acid sequence set forth in SEQ ID NO:

14.

4. A recombinant adeno-associated virus (rAAV), comprising an AAV capsid and a vector genome packaged therein, said vector genome comprising the recombinant nucleic acid of any one of claims 1 to 3.

5. The rAAV of claim 4, wherein the AAV capsid is derived from an AAV of serotype 9, 8, 1, 2, 3, 4, 5, 6, 7, 10, 11, 12, rhlO, or hu37.

6. A composition comprising the rAAV of claim 4 or claim 5 and a pharma- ceutically acceptable carrier.

7. The composition of claim 6 for treating Wilson's disease in a human subject.

8. The composition of claim 7, wherein the composition is administered subcutaneously, intramuscularly, intradermally, intraperitoneally, or intravenously.

9. The rAAV is about 1×10 １１ Genome copies (GC) / kg to about 1 x 10 １４ The composition of claim 7 or 8, administered at a dose of GC / kg.

10. The rAAV is about 5.0×10 １２ GC / kg, approximately 1.0×10 １３ GC / kg, or approximately 2.0 x 10 １３ The composition of claim 9 , administered at a dose of GC / kg.

Images